Nuclear Medicine

Nuclear medicine (also called molecular imaging) includes positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. Nuclear imaging is achieved by injecting small amounts of radioactive material (radiopharmaceuticals) into patients before or during their scan. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

RSS icon
Thumbnail

Experts say one radiotracer outperforms all others when it comes to detecting prostate cancer

There are numerous radiotracers specifically designed to identify prostate cancer, but experts say one may be superior to the others at both the patient and lesion level. 

New radiotracers outperform FDA-approved agent for detection of tau tangles.

Radiotracers on FDA’s fast track exceed performance of already approved tau-detecting agent

If approved, the two agents could offer providers greater insight into the process of patients’ neurodegeneration.

Evergreen Theragnostics

Lantheus to acquire radiopharma firm Evergreen Theragnostics for up to $1B

Founded in 2019, Evergreen develops and manufactures imaging agents aimed at diagnosing and treating cancer, including Octevy for neuroendocrine tumors. 

merger acquisition M&A business

Imaging agent developer Telix finalizes $250M purchase of RLS radiopharma network

RLS operates America’s only Joint Commission-accredited radiopharmacy network, with 31 locations covering over 85% of the U.S. population. 

Thumbnail

PET scans unlock clues that could help prevent epilepsy induced by head injuries

Post-traumatic epilepsy can be disabling, causing recurrent seizures that are unresponsive to preventive medications in up to 30% of patients.

Thumbnail

Dementia cases are about to skyrocket—how will this affect imaging demand?

Recent projections could create an environment of unprecedented demand for nuclear imaging.

Neusight PET

PET-CT seeing increasing adoption, and now more affordable systems have facilities taking a closer look

Sponsored by Positron

The American Society of Nuclear Cardiology (ASNC) says positron emission tomography (PET) nuclear imaging has seen wider adoption in the past few years, and many cardiac imaging experts say it could become the workhorse technology for nuclear cardiac assessments over the next decade. 

Lantheus

Lantheus to acquire PET agent developer Life Molecular Imaging for up to $750M

LMI is the maker of Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s

Displaying 17 - 24 of 355
Design by Adaptive Theme